Record-High Full-Year Sales and Profit Results Driven by Large-Scale Projects
First written in FY2019. . Latest entry: FY2025.
The whole theme swung hardest in 2020: 15 of 94 companies on the "Worse" side.
37 other companies' latest entry also says "Other".
- FY2025Full-year increases in sales and profit driven by growth in large projectsAnnual report
「As a result, revenue for the current consolidated fiscal year was ¥21,489.527 million, up 8.5% from the previous fiscal year. Operating income was ¥288.291 million, up 61.9%; ordinary income was ¥308.842 million, up 70.5%; and net income attributable to owners of the parent was ¥152.777 million, up 12.3%.」
Revenue, operating income, ordinary income and net income attributable to owners of the parent all exceeded the previous fiscal year's levels in FY2025, primarily due to an increase in major projects. - FY2025-H1First-half revenue and income growthAnnual report
「As a result, revenue for the current interim consolidated accounting period was ¥12,940.317 million, up 5.9% year on year. Operating income was ¥496.875 million, up 38.8%; ordinary income was ¥513.837 million, up 43.5%; and interim net income attributable to owners of the parent was ¥344.286 million, up 56.0%.」
In the first half of FY2025, revenue, operating income, ordinary income and interim net income attributable to owners of the parent all exceeded the same period of the previous year. - FY2024Revenue and earnings down due to fewer major projectsAnnual report
「Revenue for the current consolidated fiscal year was ¥19,804.248 million, down 25.6% from the previous fiscal year. Operating income was ¥178.107 million, down 59.5%; ordinary income was ¥181.146 million, down 58.0%; and net income attributable to owners of the parent was ¥136.057 million, down 49.9%.」
In FY2024, revenue and all profit measures fell below the previous fiscal year's levels. The company explained that the decline in projects worth ¥1 billion or more in its core business led to lower revenue and earnings. - FY2024-Q2First-half revenue and income growthAnnual report
「As a result, revenue for the second quarter of the current consolidated cumulative period was ¥12,216.679 million, up 4.8% year on year. Operating income was ¥357.998 million, up 36.0%; ordinary income was ¥357.958 million, up 43.6%; and net income attributable to owners of the parent was ¥220.708 million, up 53.5%.」
In the cumulative second quarter of FY2024, revenue, operating income, ordinary income and net income attributable to owners of the parent all exceeded the same period of the previous year. - FY2024-Q1Higher revenue and return to profitabilityAnnual report
「As a result, revenue for the first quarter of the current consolidated cumulative period was ¥5,413.543 million, up 9.7% year on year. Operating income was ¥136.144 million, compared with an operating loss of ¥10.733 million in the same quarter of the previous year. Ordinary income was ¥136.144 million, compared with an ordinary loss of ¥10.278 million, and net income attributable to owners of the parent was ¥80.421 million, compared with a net loss attributable to owners of the parent of ¥24.263 million.」
Revenue increased 9.7% year on year, and the company turned profitable from the operating loss, ordinary loss and net loss attributable to owners of the parent recorded in the same period of the previous year, posting operating income of ¥136.144 million, ordinary income of ¥136.144 million and net income attributable to owners of the parent of ¥80.421 million. - FY2023Revenue and earnings down due to fewer major projectsAnnual report
「In the previous fiscal year, the company recorded multiple projects worth ¥2 billion or more, including projects strategically secured. In contrast, only one project worth ¥2 billion or more was recorded in the current fiscal year, resulting in lower revenue and, consequently, lower gross profit.」
The number of major projects recorded fell from multiple projects in the previous fiscal year to one in the current fiscal year. Consolidated revenue declined 10.5% year on year and operating income declined 32.4%. - FY2023-Q3Revenue and earnings down as major projects were not recordedAnnual report
「In the cumulative third quarter of the previous consolidated fiscal year, the company recorded multiple projects worth ¥2 billion or more, including projects strategically secured. In contrast, although sales activities remained strong and generally progressed as planned in the cumulative third quarter of the current consolidated fiscal year, no projects worth ¥2 billion or more were recorded, resulting in a significant year-on-year decline in revenue.」
Although sales activities remained strong and generally progressed as planned, no projects worth ¥2 billion or more were recorded in the current period, despite several such projects being recorded in the same period of the previous year. The Medical Total Solution business therefore reported revenue of ¥15,828.654 million, down 35.1% year on year, and operating income of ¥277.208 million, down 66.3%. - FY2023-Q2Revenue and earnings down due to delays in major projectsAnnual report
「Revenue for the second quarter of the current consolidated cumulative period was ¥11,662.168 million, down 37.8% year on year. Operating income was ¥263.190 million, down 65.9%; ordinary income was ¥249.320 million, down 69.8%; and net income attributable to owners of the parent was ¥143.738 million, down 73.7%.」
Revenue, operating income, ordinary income and net income attributable to owners of the parent fell significantly below the previous year's levels because the delivery date for major projects shifted from December 2021 in the same period of the previous year to April 2023 or later in the current period. - FY2023-Q1Significant revenue decline and operating loss due to delays in the delivery of major projectsAnnual report
「As a result, revenue for the first quarter of the current consolidated cumulative period was ¥4,936.915 million, down 53.8% year on year. The operating loss was ¥10.733 million, compared with operating income of ¥529.648 million in the same quarter of the previous year. The ordinary loss was ¥10.278 million, compared with ordinary income of ¥582.786 million, and the net loss attributable to owners of the parent was ¥24.263 million, compared with net income attributable to owners of the parent of ¥388.148 million.」
In Q1 FY2023, revenue fell 53.8% year on year, and operating income, ordinary income and net income attributable to owners of the parent each turned into a loss. - FY2022-Q3Higher revenue and operating income year on yearAnnual report
「As a result, for the nine months ended the third quarter, sales were ¥25,195,466 thousand, up 17.3% year on year. Operating profit was ¥886,191 thousand, up 12.7%; ordinary profit was ¥940,767 thousand, up 17.5%; and quarterly net profit attributable to owners of the parent was ¥625,991 thousand, up 15.9%, resulting in higher sales and profit year on year.」
For the nine months ended the third quarter, sales increased 17.3%, operating profit increased 12.7%, ordinary profit increased 17.5%, and quarterly net profit attributable to owners of the parent increased 15.9%, resulting in higher sales and profit year on year. - FY2022-Q2Revenue Growth and Profit DeclineAnnual report
「As a result, for the six months ended the second quarter, sales were ¥18,756,539 thousand, up 11.1% year on year. Operating profit was ¥771,479 thousand, down 9.3%; ordinary profit was ¥824,338 thousand, down 4.5%; and quarterly net profit attributable to owners of the parent was ¥545,971 thousand, down 7.2%, resulting in lower profit than in the same period of the previous year.」
Sales increased 11.1% year on year, while operating profit decreased 9.3%, ordinary profit decreased 4.5%, and quarterly net profit attributable to owners of the parent decreased 7.2%. - FY2022-Q1Revenue and profit growth year on yearAnnual report
「As a result, for the three months ended the first quarter, sales were ¥10,678,014 thousand, up 34.0% year on year; operating profit was ¥529,648 thousand, up 30.7%; ordinary profit was ¥582,786 thousand, up 44.1%; and quarterly net profit attributable to owners of the parent was ¥388,148 thousand, up 46.1%.」
In the first quarter of FY2022, sales, operating profit, ordinary profit and quarterly net profit attributable to owners of the parent all exceeded the same period of the previous year. - FY2021Substantial full-year revenue and profit growthAnnual report
「During the consolidated fiscal year, the impact of the COVID-19 pandemic on business activities remained limited, and sales and profit remained solid. In addition, because the previous period was at a low level, the Group recorded substantial increases in both sales and profit.」
In FY2021, sales were ¥26,347,156 thousand, up 19.8% year on year; operating profit was ¥576,055 thousand, up 181.9%; and ordinary profit was ¥595,939 thousand, up 187.6%. - FY2021-Q3Significant increases in revenue and profit year on yearAnnual report
「During the nine months ended the third quarter, the impact of the COVID-19 pandemic on business activities remained limited, and the Group secured substantial increases in sales and profit compared with the same period of the previous year.」
For the nine months ended the third quarter, sales were ¥21,472,031 thousand, up 36.6% year on year, and operating profit was ¥785,995 thousand, compared with ¥22,624 thousand in the same period of the previous year, resulting in substantial year-on-year increases in sales and profit. - FY2021-Q2Higher sales and profit weighted toward the first halfAnnual report
「During the six months ended the second quarter, the impact of the COVID-19 pandemic on business activities remained limited, and the Group secured higher sales and profit than in the same period of the previous year across all business segments. In particular, the Medical Total Solutions business, its core business, had a revenue structure heavily weighted toward the first half this fiscal year. In addition, because sales and profit were low in the same period of the previous year due to large projects being between cycles, the business achieved substantial increases in both sales and profit.」
All business segments recorded year-on-year increases in sales and profit. In the Medical Total Solutions business, sales from large projects were concentrated in the first half, resulting in substantial increases in sales and profit under a revenue structure weighted toward the first half. - FY2021-Q1Higher sales and profit driven by strong performance in large projectsAnnual report
「Sales increased during the three months ended the first quarter, mainly because bulk sales of medical equipment, including projects worth approximately ¥1 billion, remained strong. Profit was also significantly above the same period of the previous year.」
Bulk sales of medical equipment, including projects worth approximately ¥1 billion, remained strong, resulting in sales of ¥7,971,544 thousand and operating profit of ¥405,213 thousand. This was a significant improvement from operating profit of ¥23,680 thousand in the same period of the previous year. - FY2020-Q3Significant decline from the previous period's record resultsAnnual report
「However, because large projects such as bulk sales of medical equipment were between project cycles during the current period, sales and all profit figures were significantly below the previous period's record highs. Accordingly, for the nine months ended the third quarter, the Group recorded sales of ¥15,724,563 thousand, down 44.3% year on year; operating profit of ¥22,624 thousand, down 98.1%; ordinary profit of ¥26,197 thousand, down 97.8%; and a quarterly net loss attributable to owners of the parent of ¥4,807 thousand, compared with quarterly net profit attributable to owners of the parent of ¥715,723 thousand in the same period of the previous year.」
Against a backdrop of large projects being between cycles, sales and all profit figures were significantly below the previous period's record results, and the Group recorded a quarterly net loss attributable to owners of the parent. - FY2019First statedAnnual report
「Both sales and profits at each stage reached record highs.」
For the fiscal year ended September 2019, sales were ¥36,109,029 thousand, operating profit was ¥1,190,179 thousand, ordinary profit was ¥1,184,035 thousand, and profit attributable to owners of the parent was ¥732,959 thousand, according to the disclosure.